The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
Open accessAbstract
Background & aims Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH.Methods We randomized 74 nondiabetic patients (45 men; median age, 54 y) with histologically proven NASH to 12 months of standard diet, exercise, and either placebo or pioglitazone (30 mg/day). Sixty-one patients (30 placebo, 31 pioglitazone) had liver biopsies both at the beginning and the end of the study.Results Compared with placebo, pioglitazone therapy was associated with an increase in weight (mean change, -0.55 vs +2.77 kg; P = .04) and a reduction in glucose (+0.4 vs -0.1 mmol/L; P = .02), HbA1c (+0.16% vs -0.18%; P = .006), insulin C peptide level (+42 vs -78 pmol/L; P = .02), alanine aminotransferase level (-10.9 vs -36.2 u/L; P = .009), gamma-glutamyltransferase level (-9.4 vs -41.2 u/L; P = .002), and ferritin (-11.3 vs -90.5 microg/L; P = .01). Histologic features including hepatocellular injury (P = .005), Mallory-Denk bodies (P = .004), and fibrosis (P = .05) were reduced in patients treated with pioglitazone compared with those in the placebo group.Conclusions Pioglitazone therapy over a 12-month period in nondiabetic subjects with NASH resulted in improvements in metabolic and histologic parameters, most notably liver injury and fibrosis. Larger extended trials are justified to assess the long-term efficacy of pioglitazone in this patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis of 8 RCTs in people with biopsy-proven MASH concluded that pioglitazone was not only associated with the improvement of MASH but also reversal of fibrosis, irrespective of the presence of type 2 diabetes [178].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [178]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Histological analysis revealed significant reductions in hepatocellular injury, Mallory–Denk bodies, and fibrosis compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [203]
The cited source says what the claim attributes to it.
In the citing paper
“In several RCTs, pioglitazone, a thiazolidinedione which mainly activates peroxisome proliferator-activated receptor (PPAR) c , has been shown to improve histological features of steatohepatitis, 372,418 -420 without a clear effect on fi brosis regression even after prolonged (3-year) therapy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [418]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
Flagged first, then by citations
Research works printed but not linked: 1
- Pfützner, 2005, Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control, Horm Metab Res, 37, 510, 10.1055/s-2005-870320 · DOI
Cited by
Sorted by citations
Items 101–200 of 718
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 197
“For example, pioglitazone is effective in improving NASH to some extent [160, 161].”
BackgroundNonalcoholic fatty liver disease in type 2 diabetes mellitus
Cusi, K. J. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283293015 · Cited by 190
Clinical Syndromes and Consequences of Antiretroviral-Related Hepatotoxicity5, 1, 3
Núñez, M. (2010) · Hepatology · doi:10.1002/hep.23716 · Cited by 176
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease
Huh, Y., Cho, Y. J., & Nam, G. E. (2022) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22021 · Cited by 192
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
VanWagner, L. B., Koppe, S., Brunt, E. M., Gottstein, J. H., Gardikiotes, K., Green, R. M., & Rinella, M. E. (2011) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31539-x · Cited by 174
Gusdon, A. M., Song, K., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 172
“Other studies using pioglitazone have shown that this thiazolidinedione is able to improve hepatic steatosis and markers of inflammation as well as decrease hepatic fibrosis [210, 211].”
Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease
Saran, A., Dave, S., & Zarrinpar, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.050 · Cited by 179
Crossan, C., Tsochatzis, E. A., Longworth, L., Gurusamy, K. S., Davidson, B. R., Rodríguez‐Perálvarez, M., Mantzoukis, K., O’Brien, J., Thalassinos, E., Papastergiou, V., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19090 · Cited by 169
Mahady, S. E., Webster, A. C., Walker, S. L., Sanyal, A. J., & George, J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.016 · Cited by 168
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 174
Ratziu, V., Sheikh, M. Y., Sanyal, A. J., Lim, J. K., Conjeevaram, H. S., Chalasani, N., Abdelmalek, M. F., Bakken, A., Renou, C., Palmer, M., et al. (2011) · Hepatology · doi:10.1002/hep.24747 · Cited by 166
“Headache 4 (15) 7 (27) 4 (17) 4 (16) 5 (22)”
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yu, Y., Cai, J., She, Z., & Li, H. (2018) · Advanced Science · doi:10.1002/advs.201801585 · Cited by 166
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chavez, C. P., Cusi, K. J., & Kadiyala, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 165
Singh, S., Khera, R., Allen, A. M., Murad, M. H., & Loomba, R. S. (2015) · Hepatology · doi:10.1002/hep.27999 · Cited by 165
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Takahashi, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3777 · Cited by 162
Meta‐analysis: insulin sensitizers for the treatment of non‐alcoholic steatohepatitis
Rakoski, M. O., Singal, A. G., Rogers, M. A. M., & Conjeevaram, H. S. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04467.x · Cited by 159
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 167
Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. J. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 159
“Two RTCs in patients with NASH and without T2DM later confirmed these findings [13, 14].”
ResultTorres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
“Although data suggest that up to 47% of patients resolve NASH with pioglitazone, improvement in hepatic fibrosis has shown modest, if any, improvement with TZD therapy.(8-11) In three previous studies with pioglitazone, fibrosis improvement was observed in 29%-46% of patients, but was not significantly different than…”
BackgroundResultNonalcoholic Fatty Liver Disease in Women
Suzuki, A., & Abdelmalek, M. F. (2009) · Women s Health · doi:10.2217/17455057.5.2.191 · Cited by 157
Kita, Y., Takamura, T., Misu, H., Ota, T., Kurita, S., Takeshita, Y., Uno, M., Nagata, N., Kato, K., Ando, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043056 · Cited by 157
“However, the effects of pioglitazone on liver pathology seem only marginal in nondiabetic patients with NASH [5].”
BackgroundJuluri, R., Vuppalanchi, R., Olson, J. D., Ünalp, A., Natta, M. L. V., Cummings, O. W., Tonascia, J. A., & Chalasani, N. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181dd1348 · Cited by 150
Reversal of liver cirrhosis: current evidence and expectations
Jung, Y. K., & Yim, H. J. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.268 · Cited by 163
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 173
Nonalcoholic Fatty Liver Disease
Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 158
Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease
Kostrzewski, T. M., Cornforth, T. V., Snow, S., Ouro-Gnao, L., Rowe, C., Large, E. M., & Hughes, D. J. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i2.204 · Cited by 152
Revision and update on clinical practice guideline for liver cirrhosis
Suk, K. T., Baik, S. K., Yoon, J., Cheong, J. Y., Paik, Y. H., Lee, C. H., Kim, Y. S., Lee, J. W., Kim, D. J., Cho, S. W., et al. (2012) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2012.18.1.1 · Cited by 142
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 150
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Shields, W., Thompson, K., Grice, G. A., Harrison, S. A., & Coyle, W. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09105462 · Cited by 141
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 143
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
Saponaro, C., Gaggini, M., & Gastaldelli, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0607-4 · Cited by 145
Cusi, K. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 141
The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
Iqbal, U., Perumpail, B. J., Akhtar, D. H., Kim, D., & Ahmed, A. (2019) · Medicines · doi:10.3390/medicines6010041 · Cited by 143
“Multiple studies have shown the benefit of pioglitazone in improving the biochemical and histological parameters of NASH [56,57].”
BackgroundBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Han, M. A. T., Altayar, O., Hamdeh, S., Takyar, V. K., Rotman, Y., Etzion, O., Lefebvre, E. A., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135
Clinical approaches to non-alcoholic fatty liver disease
Schwenger, K. J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1712 · Cited by 139
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis
Malik, S. M., DeVera, M., Fontes, P., Shaikh, O. S., Sasatomi, E., & Ahmad, J. (2009) · Liver Transplantation · doi:10.1002/lt.21943 · Cited by 131
“NASH patients who developed recurrent disease were initially treated with a combination of vitamin C, vitamin E, and ursodiol(41) without obvious improvement, and 2 patients were started on pioglitazone after the recent study demonstrating its effectiveness in patients with NASH with or without insulin resistance.(42,…”
BackgroundHe, X., Wu, X., Chen, R., Chen, C., Liu, X., Wu, B.-J., & Huang, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162368 · Cited by 129
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
Garinis, G. A., Fruci, B., Mazza, A., Siena, M. D., Abenavoli, S., Gulletta, E., Ventura, V., Greco, M., Abenavoli, L., & Belfiore, A. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.40 · Cited by 127
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 128
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 133
“Pioglitazone PPAR γ agonist Insulin sensitivity(↑) Hepatic TG(↓) ALT(↓) AST(↓) BW(↑) Steatosis(↓) Ballooning(↓) Inflammation(↓) Fibrosis(↓) NAS(↓) Phase 4 trial, 2008–2014 [104,105,125,212,213]”
FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Carr, R. M., & Reid, A. E. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0500-2 · Cited by 126
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Boeckmans, J., Natale, A., Rombaut, M., Buyl, K., Rogiers, V., Kock, J. D., Vanhaecke, T., & Rodrigues, R. M. (2019) · Cells · doi:10.3390/cells9010037 · Cited by 126
“Pioglitazone also improved liver injury and fibrosis in non-diabetic NASH patients [56].”
BackgroundLiver fibrosis: Common mechanisms and antifibrotic therapies
Schuppan, D. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.05.005 · Cited by 126
Shavakhi, A., Minakari, M., Firouzian, H., Assali, R., Hekmatdoost, A., & Ferns, G. A. (2013) · Europe PMC (PubMed Central) · Cited by 121
The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis
Kanwar, P., & Kowdley, K. V. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.002 · Cited by 126
Pharmacological advances in mitochondrial therapy
Singh, A., Faccenda, D., & Campanella, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103244 · Cited by 128
“Significant reductions in metabolic parameters including ALT aminotransferase, gamma-glutamyltransferase and ferritin were also observed [104].”
BackgroundStefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J., Nowotny, P., KAHL, S., Harreiter, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70170-0 · Cited by 113
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
(2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.4.325 · Cited by 115
Pοlyzos, S. A., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.013 · Cited by 113
“[25] Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al.”
BackgroundThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M., Mattison, D. R., Azoulay, L., & Krewski, D. R. (2017) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 117
“The use of TZDs in the treatment of NASH has been explored in numerous clinical studies (e.g. NeuschwanderTetri et al. 2003; Promrat et al. 2004; Belfort et al. 2006; Aithal et al. 2008; Idilman et al. 2008; Ratziu et al. 2008; Sanyal et al. 2010), with differing results.”
BackgroundDixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 118
“patients without T2DM also showed a significant improvement in the fibrosis stage with a daily dose of 30 mg pioglitazone [20].”
BackgroundGao, X., Fan, J., & Study Group of Liver and Metabolism, C. S. O. E. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12056 · Cited by 115
Pioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S. A., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 115
Liver disease and diabetes: Association, pathophysiology, and management
Ahmadieh, H., & Azar, S. T. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.003 · Cited by 112
Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 115
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 114
Nonalcoholic Fatty Liver Disease
Kopec, K. L., & Burns, D. L. (2011) · Nutrition in Clinical Practice · doi:10.1177/0884533611419668 · Cited by 114
“Although most studies have been focused on diabetics, at least one major publication demonstrated benefits in nondiabetics, showing reductions in inflammation as well as fibrosis at 1-year follow-up.(78) Studies with rosiglitazone have been less numerous, but the drug has also been noted to be beneficial, showing impr…”
BackgroundReview: Treatment options for nonalcoholic fatty liver disease
Lam, B. P., & Younossi, Z. M. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09359964 · Cited by 108
“Rosiglitazone and pioglitazone continue to be used and both improve insulin sensitivity and aminotransferases [Aithal et al. 2008; Ratziu et al. 2008; Neuschwander-Tetri et al. 2003].”
BackgroundInfluentialNonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 109
Non-alcoholic fatty liver disease: a practical approach to treatment
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100404 · Cited by 113
VILAR GOMEZ, E., RODRIGUEZ DE MIRANDA, A., GRA ORAMAS, B., ARUS SOLER, E., LLANIO NAVARRO, R., CALZADILLA BERTOT, L., YASELLS GARCIA, A., & DEL ROSARIO ABREU VAZQUEZ, M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04122.x · Cited by 105
Lee, Y., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E., Cho, Y. M., & Lee, B. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 106
“Similar to previous studies (22,25), we also observed greater reductions in the ALT levels of responders, compared with those observed in non-responders, following treatment.”
BackgroundResultSaid, A., & Akhter, A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.0284 · Cited by 111
Gastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Current therapeutic strategies in non‐alcoholic fatty liver disease
Dowman, J. K., Armstrong, M. J., Tomlinson, J., & Newsome, P. N. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01403.x · Cited by 100
Reversibility of liver fibrosis
Ramachandran, P., & Iredale, J. P. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31740-5 · Cited by 99
Anti-fibrotic therapy: Lost in translation?
Schuppan, D., & Pinzani, M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60008-7 · Cited by 97
Hajiaghamohammadi, A. A., Ziaee, A., Oveisi, S., & Masroor, H. (2012) · Hepatitis Monthly · doi:10.5812/hepatmon.6099 · Cited by 97
Fatty liver as a consequence and cause of insulin resistance: Lessons from type 2 diabetic liver
Takamura, T., Misu, H., Ota, T., & Kaneko, S. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0228 · Cited by 96
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96
Majzoub, A. M., Nayfeh, T., Barnard, A., Munaganuru, N., Dave, S., Singh, S., Murad, M. H., & Loomba, R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16583 · Cited by 92
Nonalcoholic fatty liver disease
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 95
Younossi, Z. M., Reyes, M. J., Mishra, A., Mehta, R., & Henry, L. L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12543 · Cited by 93
“study, patients receiving pioglitazone showed improved histology and fibrosis.(30) On the other hand, the PIVENS trial randomly assigned 247 nondiabetic patients with NASH to one of three groups: pioglitazone, vitamin E or placebo group.”
BackgroundMitochondrial Dysfunction in the Transition from NASH to HCC
Léveillé, M., & Estall, J. L. (2019) · Metabolites · doi:10.3390/metabo9100233 · Cited by 94
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Edwards, C., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.007 · Cited by 94
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 92
Targher, G., Marchesini, G., & Byrne, C. D. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.04.002 · Cited by 90
Athyros, V. G., Pοlyzos, S. A., Kountouras, J., Katsiki, N., Anagnostis, P. G., Doumas, M. N., & Mantzoros, C. S. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164313 · Cited by 87
Pydyn, N., Miękus, K., Jura, J., & Kotlinowski, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00020-1 · Cited by 89
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 88
PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
Monroy-Ramírez, H. C., Galicia‐Moreno, M., Sandoval-Rodriguez, A. S., Meza-Ríos, A., Santos, A., & Armendáriz‐Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158298 · Cited by 86
Diabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Stein, L. L., Dong, M. H., & Loomba, R. S. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0072-z · Cited by 85
Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
Therapy of nonalcoholic fatty liver disease: current status.
Duvnjak, M., Tomašić, V., Gomerčić, M., Duvnjak, L. S., Baršić, N., & Lerotić, I. (2009) · PubMed · Cited by 82
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 87
Flessa, C., Kyrou, I., Ansari, N. N., Kaltsas, G., Papavassiliou, A. G., Kassi, E. N., & Randeva, H. S. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00431-3 · Cited by 81
Management of NAFLD in primary care settings
Wong, V. W., Zelber‐Sagi, S., Cusi, K. J., Carrieri, P., Wright, E. E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 84
Primary care practitioners survey of non-alcoholic fatty liver disease
Said, A., Gagovic, V., Malecki, K. M. C., Givens, M. L., & Nieto, F. J. (2013) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31317-1 · Cited by 83
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 84
“A mild increase of HDL-C, paralleling that in the placebo group, and regression in TG were observed in the fenofibrate group [175].”
Balmer, M. L., Siegrist, K., Zimmermann, A., & Dufour, J. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02037.x · Cited by 78
“In the last decade, it has been realized that cytokines produced by the adipose tissue (adipokines) such as leptin, adiponectin, resistin and retinol binding protein (RBP)-4, regulate insulin sensitivity and participate in the pathogenesis of NASH (4, 5, 10, 11).”
BackgroundBallestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 79
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
VanWagner, L. B., & Rinella, M. E. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11403809 · Cited by 77
“The benefit safety profile of TZDs, as well as the possible eventual benefit on hepatic fibrosis, warrants further assessment in larger RCTs of longer duration.”
BackgroundMethodResultInfluentialZhang, L., Qu, X.-N., Sun, Z.-Y., & Zhang, Y. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.01.007 · Cited by 78
Metadata
- Authors
- Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J.
- Affiliations
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- Royal Derby Hospital (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Corresponding author
- Aithal, Guruprasad P.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 135
- Issue
- 4
- Pages
- 1176-1184
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2151490108
- Cited by
- 721
- References
- 39
- Citations by year
- 2026: 15 · 2025: 33 · 2024: 34 · 2023: 38 · 2022: 51 · 2021: 54 · 2020: 48 · 2019: 35 · 2018: 34 · 2017: 36 · 2016: 45 · 2015: 42 · 2014: 40 · 2013: 38 · 2012: 35
- FWCI
- 35.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, thiazolidinediones, non-diabetic patients, liver fibrosis, liver histopathology, insulin sensitivity, insulin resistance, hepatocyte injury, Mallory-Denk bodies, alanine aminotransferase, ferritin, weight change, glycemic control
- MeSH terms
- Pioglitazone, Adult, Aged, Alkaline Phosphatase, Fatty Liver, Female, Humans, Hypoglycemic Agents, Insulin, Liver, Liver Cirrhosis, Male, Middle Aged, Patient Dropouts, Placebos, Treatment Outcome, Thiazolidinediones, Adipokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
